Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.
COVID-19
Coronavirus Infections
/ drug therapy
Drug Compounding
Drugs, Chinese Herbal
/ adverse effects
Humans
Materia Medica
/ adverse effects
Medicine, Chinese Traditional
/ standards
Pandemics
/ prevention & control
Patient Safety
Pharmacopoeias as Topic
Pneumonia, Viral
/ prevention & control
Public Health
Quality Control
COVID-19 Drug Treatment
Chinese Materia Medica
Coronavirus disease 2019
ISO/TC 249
Quality standards
Traditional Chinese medicine
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
25
04
2020
revised:
02
07
2020
accepted:
07
07
2020
pubmed:
13
7
2020
medline:
26
11
2020
entrez:
13
7
2020
Statut:
ppublish
Résumé
Traditional Chinese medicine (TCM) has fully engaged and played an essential role in the prevention and treatment of Coronavirus Disease 2019 (COVID-19). This study compares relevant standards on high-frequent Chinese Materia Medicia (CMM) used in this pandemic aiming at reaching a global consensus and ensuring the use of Chinese medicines safely. 141 representative Chinese formulas and Chinese Patent Medicines from the National Protocol and the most of Provincial Protocols for controlling COVID-19 in China have been collected to statistical analyze the composition and characteristics of CMM. Among them, the domestic and international standards of 47 varieties with the frequency usage over 10 times were selected to compare their quality requirements in the mainstream pharmacopoeias and international standards. The quality requirements of used CMM for fighting COVID-19 on the terms of overall quality control, marker compounds, and safety indicators showed different patterns in these mainstream pharmacopoeias and international standards. The uniformed and scientific quality standards of CMM were urgently needed to promote global acceptation and trade. These findings will provide evidence for building unified quality and safety standards that can adapt to the characteristics of CMM and promote international trade, and also will be stated that it is of the highest priority for ISO/TC 249 to formulate high-quality standards that consolidate international consensus to ensure quality and safety of the urgently needed CMM.
Identifiants
pubmed: 32653649
pii: S1043-6618(20)31382-7
doi: 10.1016/j.phrs.2020.105074
pmc: PMC7347313
pii:
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Materia Medica
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105074Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Int J Biol Sci. 2020 Mar 15;16(10):1708-1717
pubmed: 32226288
Pharmacol Res. 2020 Aug;158:104896
pubmed: 32438037
Pharmacol Res. 2020 Jul;157:104882
pubmed: 32380051
Am J Chin Med. 2020;48(3):737-762
pubmed: 32164424
Pharmacol Res. 2020 May;155:104768
pubmed: 32222346
Phytomedicine. 2018 May 15;44:204-211
pubmed: 29551645
Chin Med. 2018 Feb 9;13:9
pubmed: 29449877
Front Med. 2020 Apr;14(2):210-214
pubmed: 32170559
Chin Med. 2020 Apr 15;15:34
pubmed: 32308732
Phytomedicine. 2021 May;85:153242
pubmed: 33867046
Chin Med. 2018 Oct 11;13:50
pubmed: 30337951